206 related articles for article (PubMed ID: 28178664)
21. Clinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experience.
Erdogan EG; Yalta TD; Can N; Süt N; Taştekin E; Usta U; Puyan FÖ; Usturalı Keskin FE; Kurt BB
Indian J Pathol Microbiol; 2023; 66(3):449-455. PubMed ID: 37530323
[TBL] [Abstract][Full Text] [Related]
22. Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group.
Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
Gynecol Oncol; 2016 Jun; 141(3):447-453. PubMed ID: 27072806
[TBL] [Abstract][Full Text] [Related]
23. Co-expression Analysis of Genes and Tumor-Infiltrating Immune Cells in Metastatic Uterine Carcinosarcoma.
Huang R; Sun H; Yan G; Zhang L; Sun W; Zhang J; Yin H; Xian S; Hu P; Yan P; Zhu X; Meng T; Wang J; Huang Z
Reprod Sci; 2021 Sep; 28(9):2685-2698. PubMed ID: 33905082
[TBL] [Abstract][Full Text] [Related]
24. Expression of aurora kinases: Predictor of tumor dissemination in uterine carcinosarcoma.
Han KH; Kim MA; Park NH
Histol Histopathol; 2017 Jul; 32(7):717-724. PubMed ID: 27779297
[TBL] [Abstract][Full Text] [Related]
25. Is minimally invasive surgery for clinical stage I uterine carcinosarcoma safe?
Sinha R; Nizam A; Shan W; Shih KK; Frimer M; Sakaris A; Goldberg GL
J Robot Surg; 2022 Aug; 16(4):943-949. PubMed ID: 34716874
[TBL] [Abstract][Full Text] [Related]
26. Fascin Is Associated With Aggressive Behavior and Poor Outcome in Uterine Carcinosarcoma.
Richmond AM; Blake EA; Torkko K; Smith EE; Spillman MA; Post MD
Int J Gynecol Cancer; 2017 Nov; 27(9):1895-1903. PubMed ID: 28704324
[TBL] [Abstract][Full Text] [Related]
27. Rare uterine cancer: carcinosarcomas. Review from histology to treatment.
Artioli G; Wabersich J; Ludwig K; Gardiman MP; Borgato L; Garbin F
Crit Rev Oncol Hematol; 2015 Apr; 94(1):98-104. PubMed ID: 25468677
[TBL] [Abstract][Full Text] [Related]
28. Uterine carcinosarcoma: An overview.
Pezzicoli G; Moscaritolo F; Silvestris E; Silvestris F; Cormio G; Porta C; D'Oronzo S
Crit Rev Oncol Hematol; 2021 Jul; 163():103369. PubMed ID: 34051304
[TBL] [Abstract][Full Text] [Related]
29. Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment.
An Y; Wang S; Li S; Zhang L; Wang D; Wang H; Zhu S; Zhu W; Li Y; Chen W; Ji S; Guo X
BMC Cancer; 2017 Sep; 17(1):639. PubMed ID: 28893210
[TBL] [Abstract][Full Text] [Related]
30. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
[TBL] [Abstract][Full Text] [Related]
31. Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma.
Desai NB; Kollmeier MA; Makker V; Levine DA; Abu-Rustum NR; Alektiar KM
Gynecol Oncol; 2014 Oct; 135(1):49-53. PubMed ID: 25084509
[TBL] [Abstract][Full Text] [Related]
32. Integrated Molecular Characterization of Uterine Carcinosarcoma.
Cherniack AD; Shen H; Walter V; Stewart C; Murray BA; Bowlby R; Hu X; Ling S; Soslow RA; Broaddus RR; Zuna RE; Robertson G; Laird PW; Kucherlapati R; Mills GB; ; Weinstein JN; Zhang J; Akbani R; Levine DA
Cancer Cell; 2017 Mar; 31(3):411-423. PubMed ID: 28292439
[TBL] [Abstract][Full Text] [Related]
33. [Clinicopathological and gene mutation characteristics of uterine carcinosarcoma].
Tu J; Xu JZ; Zhang YS; Deng LF
Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(24):1864-1867. PubMed ID: 37357193
[TBL] [Abstract][Full Text] [Related]
34. Uterine carcinosarcoma.
Arend R; Doneza JA; Wright JD
Curr Opin Oncol; 2011 Sep; 23(5):531-6. PubMed ID: 21743326
[TBL] [Abstract][Full Text] [Related]
35. [Uterine carcinosarcoma].
Serkies K; Jassem J
Ginekol Pol; 2012 Aug; 83(8):609-12. PubMed ID: 23342885
[TBL] [Abstract][Full Text] [Related]
36. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study.
Sartori E; Bazzurini L; Gadducci A; Landoni F; Lissoni A; Maggino T; Zola P; La Face B
Gynecol Oncol; 1997 Oct; 67(1):70-5. PubMed ID: 9345359
[TBL] [Abstract][Full Text] [Related]
37. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
[TBL] [Abstract][Full Text] [Related]
38. Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS.
Chiba Y; Sato S; Itamochi H; Suga Y; Fukagawa T; Oumi N; Oishi T; Harada T; Sugai T; Sugiyama T
Hum Cell; 2017 Apr; 30(2):140-148. PubMed ID: 27889902
[TBL] [Abstract][Full Text] [Related]
39. S100A4/non-muscle myosin II signaling regulates epithelial-mesenchymal transition and stemness in uterine carcinosarcoma.
Tochimoto M; Oguri Y; Hashimura M; Konno R; Matsumoto T; Yokoi A; Kodera Y; Saegusa M
Lab Invest; 2020 May; 100(5):682-695. PubMed ID: 31857700
[TBL] [Abstract][Full Text] [Related]
40. Role of TGF-β signaling in uterine carcinosarcoma.
Dwivedi SK; McMeekin SD; Slaughter K; Bhattacharya R
Oncotarget; 2015 Jun; 6(16):14646-55. PubMed ID: 25918253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
